Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy
Korean Journal of Ophthalmology
;
: 139-142, 2012.
Article
in English
| WPRIM
| ID: wpr-40416
ABSTRACT
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 +/- 0.25 to 0.50 +/- 0.18 and 0.29 +/- 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 +/- 65 to 208 +/- 23 microm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Visual Acuity
/
Follow-Up Studies
/
Treatment Outcome
/
Angiogenesis Inhibitors
/
Tomography, Optical Coherence
/
Central Serous Chorioretinopathy
/
Intravitreal Injections
/
Antibodies, Monoclonal, Humanized
Type of study:
Observational study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
English
Journal:
Korean Journal of Ophthalmology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS